Prenatal and Pregnancy Management of Congenital Adrenal Hyperplasia.

Autor: Nowotny HF; Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany., Tschaidse L; Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany., Auer MK; Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany., Reisch N; Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Jazyk: angličtina
Zdroj: Clinical endocrinology [Clin Endocrinol (Oxf)] 2024 Oct; Vol. 101 (4), pp. 359-370.
DOI: 10.1111/cen.15131
Abstrakt: Management of patients with congenital adrenal hyperplasia (CAH) poses challenges during pregnancy and prenatal stages, impacting fertility differently in men and women. Women with CAH experience menstrual irregularities due to androgen and glucocorticoid precursor interference with endometrial development and ovulation. Genital surgeries for virilization and urogenital anomalies further impact fertility and sexual function, leading to reduced heterosexual relationships among affected women. Fertility rates vary, with a lower prevalence of motherhood, primarily among those with classic CAH, necessitating optimized hormonal therapy for conception. Monitoring optimal disease control during pregnancy poses challenges due to hormonal fluctuations. Men with CAH often experience hypogonadotrophic hypogonadism and complications like testicular adrenal rest tissue, impacting fertility. Regular monitoring and intensified glucocorticoid therapy may restore spermatogenesis. Genetic counselling is vital to comprehend transmission risks and prenatal implications. Prenatal dexamethasone treatment in affected female fetuses prevents virilization but raises ethical and safety concerns, necessitating careful consideration and further research. The international "PREDICT" study aims to establish safer and more effective prenatal therapy in CAH, evaluating dosage, safety, and long-term effects.
(© 2024 John Wiley & Sons Ltd.)
Databáze: MEDLINE